https://orcid.org/0000-0003-2318-8627
References
- Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(7):460–473. doi:10.1016/j.clml.2022.01.011
- Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed–refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12(6):98. doi:10.1038/s41408-022-00695-5
- European Medicines Agency (EMA). ABECMA (idecabtagene vicleucel); 2021 [updated 2022 Dec 21]. Available from: https://www.ema.europa.eu/en/documents/product-information/abecma-epar-product-information_en.pdf
- Food and Drug Administration. ABECMA (idecabtagene vicleucel); 2021 [updated 2021 Apr 21]. Available from: https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel
- European Medicines Agency (EMA). BLENREP (belantamab mafodotin): EU summary of product characteristics; 2020. Available from: https://ec.europa.eu/health/documents/community-register/2020/20200825148987/anx_148987_en.pdf
- GlaxoSmithKline. GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization [press release]; 2023 [cited 2023 Jun 19]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/
- Rodriguez-Otero P, Ayers D, Cope S, et al. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2021;62(10):2482–2491. doi:10.1080/10428194.2021.1913143
- Shah N, Ayers D, Cope S, et al. Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel vs belantamab mafodotin: a matching-adjusted indirect comparison study. HemaSphere. 2022;6(Suppl. 3):1621–1622. doi:10.1097/01.HS9.0000849816.07364.24
- Anderson LD Jr., Shah N, Jagannath S, et al. OAB-027: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa [abstract]. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl. 2):S17–S18. doi:10.1016/S2152-2650(21)02101-7
- Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study. Cancer. 2021;127(22):4198–4212. doi:10.1002/cncr.33809
- Delforge M, Shah N, Miguel JSF, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6(4):1309–1318. doi:10.1182/bloodadvances.2021005913
- Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221. doi:10.1016/S1470-2045(19)30788-0
- Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:10.1186/1471-2288-12-9
- Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211. doi:10.1177/0272989X17725740
- Li X, Liu J, Chen M, et al. Health‐related quality of life of patients with multiple myeloma: a real‐world study in China. Cancer Med. 2020;9(21):7896–7913. doi:10.1002/cam4.3391